Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Src kinase inhibitor
DRUG CLASS:
Src kinase inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
dasatinib (215)
bosutinib (46)
TPX-0022 (8)
AZD0530 (7)
BAL3833 (4)
NXP900 (3)
PP2 (2)
TPX-0046 (2)
AZD 0424 (0)
JNJ-26483327 (0)
tirbanibulin ointment (0)
XL228 (0)
KX2-391 oral (0)
dasatinib (215)
bosutinib (46)
TPX-0022 (8)
AZD0530 (7)
BAL3833 (4)
NXP900 (3)
PP2 (2)
TPX-0046 (2)
AZD 0424 (0)
JNJ-26483327 (0)
tirbanibulin ointment (0)
XL228 (0)
KX2-391 oral (0)
›
Associations
(288)
News
Trials
Search handles
@DrHKantarjian
@FadiHaddad_MD
@jayastuMD
Search handles
@DrHKantarjian
@FadiHaddad_MD
@jayastuMD
Filter by
Latest
10ms
➡️ The evolving paradigm of therapy in T-cell ALL by @NitinJainMD at US AML/ALL focus meet @_MDEducation ✅ Bcl2/BclXL inhibitors ✅ CD 7 CAR-Ts ✅ LCK inhibition by Dasatinib/Ponatinib https://t.co/btUp5uOKaW (@jayastuMD)
10 months ago
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
|
dasatinib • Iclusig (ponatinib)
10ms
Great talk by @NitinJainMD on T-ALL ➡️ CAR-T cells being optimized with promising results ➡️ Rationale for inhibition of BCL-2 BCL-xl ➡️ LCK in 40% of T-ALL sensitive to dasatinib/ponatinib. Clinical trial at @MDAndersonNews with chemo-VEN-ponatinib #leusm #ALL @_MDEducation (@FadiHaddad_MD)
10 months ago
Clinical • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
|
dasatinib • Iclusig (ponatinib)
10ms
Dasatinib 50 mg daily is as effective and less toxic than 100 mg daily for newly diagnosed CML-CP Georgina Gener-Ricos @FadiHaddad_MD @MDAndersonNews @OncologyAdvance https://t.co/FbCwkDpo11 #leusm #CML (@DrHKantarjian)
10 months ago
dasatinib
11ms
Recently published📰: A phase I trial of #palbociclib and #bosutinib with #fulvestrant in patients with metastatic HR+ HER2- #BreastCancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor by @FilipaLynce @EDBarrowsMD @juliecollinsmd @claudine_isaacs @ppohlmann_ et al (@DFCI_BreastOnc)
11 months ago
Clinical • P1 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Ibrance (palbociclib) • fulvestrant • Bosulif (bosutinib)
over2years
Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered #Prostate tumors. #BeyondTheAbstract with @Goutam_Chak and @DrPhilKantoff @sloan_kettering. #ReadNow on UroToday > https://t.co/TPLlWycHV1 @CCR_AACR (@urotoday)
over 2 years ago
Synthetic lethality
|
BRCA2 (Breast cancer 2, early onset)
almost3years
Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered #Prostate tumors. #BeyondTheAbstract with @Goutam_Chak and @DrPhilKantoff @sloan_kettering. #ReadNow on UroToday > https://t.co/TPLlWycHV1 @CCR_AACR (@urotoday)
almost 3 years ago
Synthetic lethality
|
BRCA2 (Breast cancer 2, early onset)
over3years
Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors. 𝘾𝙡𝙞𝙣 𝘾𝙖𝙣𝙘𝙚𝙧 𝙍𝙚𝙨. @DrPhilKantoff #ProstateCancer https://t.co/DjcVhQHiPi (@CaP_pubs)
over 3 years ago
BRCA2 (Breast cancer 2, early onset)
almost7years
Phase 1 study bevacizumab+dasatinib with interesting activity in #endometrial cancer @ASCO @NCIResearchCtr #ASCO17 (@CMAnnunziata)
almost 7 years ago
P1 data
|
Avastin (bevacizumab) • dasatinib
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login